The FIGHT study did not find significant changes in LVEF, pro-BNP, HbA1c, heart rate, LV end-systolic volume index, LV end-diastolic volume index, and 6-min walking when DM patients with HFrEF were treated with liraglutide for 6 months in comparison with placebo control group [39]. The gene discussed is NPPB; the disease is diabetes mellitus.